Dravet Syndrome

Also known as: Severe myoclonic epilepsy of infancy / Epilepsy, Myoclonic, Infantile, Severe

DrugDrug NameDrug Description
DB09118StiripentolStiripentol is an anticonvulsant drug used in the treatment of epilepsy as an adjunct therapy along with [DB00349] and [DB00313]. Unrelated to other anticonvulsants, stitipentol belongs to the group of aromatic allylic alcohols and may potentiate the effect of other antiepileptic drugs (AEDs) due to pharmacokinetic interactions. It elevates the levels of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter that regulates electrical activity in the central nervous system. Use of stiripentol is approved for infants with Dravet syndrome, or Severe Myoclonic Epilepsy in Infancy (SMEI) that commonly occurs at the first year of life. Stiripentol is not FDA-approved but approved in Canada and European countries as oral tablets marketed as Diacomit.
DrugDrug NamePhaseStatusCount
DB09061Cannabidiol2Completed1
DB00661Verapamil2Completed1
DB09061Cannabidiol3Completed1
DB09061Cannabidiol3Enrolling by Invitation1
DB09061Cannabidiol3Recruiting1
DB09061Cannabidiol3Withdrawn1
DB00349Clobazam3Terminated1
DB00349Clobazam3Withdrawn1
DB00574Fenfluramine3Active Not Recruiting1
DB00574Fenfluramine3Enrolling by Invitation2
DB09118Stiripentol4No Longer Available1
DB09118StiripentolNot AvailableAvailable3